Placebo News and Research

RSS

Nutrient cocktail can boost memory in patients with mild cognitive impairment

A clinical trial of an Alzheimer's disease treatment developed at MIT has found that the nutrient cocktail can improve memory in patients with early Alzheimer's. The results confirm and expand the findings of an earlier trial of the nutritional supplement, which is designed to promote new connections between brain cells.

11 Jul 2012

Biomarkers predict benefit of targeted therapy in metastatic renal-cell cancer

In metastatic renal-cell cancer, the level of cytokines and angiogenic factors identify those patients with an aggressive disease course who derive the greatest benefit from treatment with the molecular-targeted therapy pazopanib, a retrospective analysis of clinical trials shows.

10 Jul 2012

Efficacy of steroids for heel pain confirmed

The efficacy of a single steroid injection for plantar fasciitis has been proven over placebo in one of the few controlled trials of the treatment.

10 Jul 2012

Two-drug combo increases diabetes patients’ goal achievement

Post-hoc analysis of randomized trial results shows that treating individuals with Type 2 diabetes with a combination of phentermine and topiramate increases their achievement of goals recommended for the management of their condition.

10 Jul 2012

High-dose vitamin D recommended for over 65s

Meta-analysis findings support recommendations from the Institute of Medicine that people aged 65 years and older should routinely receive 800 IU of vitamin D per day.

10 Jul 2012

Lesogaberan development halts following disappointing results

Lesogaberan is only marginally superior to placebo in gastroesophageal reflux disease patients who are partially responsive to proton pump inhibitor therapy, results show.

10 Jul 2012

Neuroprotective effects underpin fingolimod benefits in MS

Fingolimod therapy reduces inflammatory activity and tissue loss in the brains of patients with multiple sclerosis, shows further analysis of the FREEDOMS trial.

10 Jul 2012

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Human Genome Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

10 Jul 2012

MiR-33 plays a key role in regulating bile metabolism

In research funded by the National Institutes of Health and the American Heart Association and published in EMBO Molecular Medicine, Saint Louis University investigator -ngel Bald-n, Ph.D., found that the microRNA miR-33 plays a key role in regulating bile metabolism. Further, the research suggests that, in an animal model, the manipulation of this microRNA can improve the liver toxicity that can be caused by statins.

10 Jul 2012

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inovio Pharmaceuticals, Inc. announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon universal influenza vaccine.

10 Jul 2012

Iron supplementation decreases fatigue by almost 50% in nonanemic women

Iron supplementation reduced fatigue by almost 50% in women who are low in iron but not anemic, according to the results of a clinical trial published July 9 in CMAJ (Canadian Medical Association Journal).

10 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012

Treating Sickle Cell Disease with L-Glutamine

By focusing on how best to help patients, researchers can sometimes find solutions that are much simpler than anticipated. That has been the guiding approach to our efforts to develop a treatment for sickle cell disease.

3 Jul 2012

Botulinum toxin may help prevent arm tremor in people with MS

Botulinum toxin may help prevent shaking or tremor in the arms and hands of people with multiple sclerosis (MS), according to new research published in the July 3, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

3 Jul 2012

Savient's KRYSTEXXA improves HRQOL and physical function in patients with RCG

Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.

3 Jul 2012

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positive.

2 Jul 2012

Vitamin D–calcium combo reduces mortality in elderly

The results of a meta-analysis of individual patient data show that vitamin D supplementation with calcium reduces mortality rates in the elderly.

2 Jul 2012

Folic acid ‘may benefit diabetics’

Folic acid supplementation can significantly reduce homocysteine levels and may therefore offer an approach for lowering cardiovascular risk among patients with Type 2 diabetes, report researchers.

2 Jul 2012

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012